At Mount Sinai, the integration of cutting-edge genomic technologies into clinical practice is driving significant advancements in patient care. One example of this innovation is the collaboration between Matthew Galsky, MD, an oncologist specializing in bladder cancer, and the experts at the Center for Advanced Genomics Technology (CAGT). Together, they’ve utilized advanced genomic tools, such as single-cell analysis and high-resolution gene expression mapping, to explore immune responses in cancer with unprecedented detail.
This collaboration has led to groundbreaking discoveries, inspiring the development of new clinical trials aimed at enhancing patient outcomes. Dr. Galsky’s partnership with CAGT is just one of many at Mount Sinai, where clinicians across various specialties work closely with genomic scientists to translate research into real-world clinical solutions with advanced technology development.
Through these collaborations, Mount Sinai is at the forefront of integrating new technologies into healthcare, transforming how diseases are understood and treated, and offering new hope to patients across numerous fields.
Professor of Medicine (Hematology and Medical Oncology) and Urology Director of Genitourinary Medical Oncology Co-Director, Center of Excellence for Bladder Cancer Associate Director for Translational Research at The Tisch Cancer Institute